OS Therapies Announces Clinical Update From Ongoing Phase 2b Clinical Trial Of Its Immunotherapy OST-HER2 (OST31-154) In Patients With Resected, Recurrent Osteosarcoma
1-year Event Free Survival (EFS) of 32.5% vs. 20% 1-year EFS for comparatorInterim 1-year and 18-month Overall Survival (OS) of 90.4%0 Grade 3, 4 or 5 Treatment-related Adverse Events (AEs)41 patient trial fully